21 CFR Part 1271 Regulatory Knowledge Map

This visual framework summarizes the regulatory concepts governing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under 21 CFR Part 1271.

The regulation is organized across multiple operational components including Subparts A–D, which address general provisions, establishment registration, donor eligibility determination, and current good tissue practice requirements.

The map illustrates how regulatory criteria such as minimal manipulation, homologous use, donor eligibility determination, and Current Good Tissue Practice (cGTP) interact when evaluating whether a product may qualify under Section 361 of the Public Health Service Act.

Regulatory classification may depend on product processing methodology, intended use context, labeling representations, and federal interpretation.

A detailed overview of the regulatory framework can be found in the 21 CFR Part 1271 Section 361 Regulatory Framework.

This information is provided for educational purposes only. Certain referenced materials may be regulated as Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under 21 CFR Part 1271. Registration with the U.S. Food and Drug Administration does not constitute FDA approval, clearance, or evaluation of safety or effectiveness. These materials are not intended to diagnose, treat, cure, or prevent any disease. For use by licensed medical professionals.